Oragenics (NYSEAMERICAN:OGEN) Trading 0.2% Higher – Time to Buy?

Oragenics, Inc. (NYSEAMERICAN:OGEN)’s stock price rose 0.2% during trading on Tuesday . The company traded as high as $0.5490 and last traded at $0.5489. Approximately 31,024 shares were traded during mid-day trading, an increase of 28% from the average daily volume of 24,280 shares. The stock had previously closed at $0.5480.

Oragenics Price Performance

The stock’s 50 day moving average price is $0.56 and its two-hundred day moving average price is $0.64. The firm has a market capitalization of $2.39 million, a price-to-earnings ratio of -0.02 and a beta of 1.24.

Oragenics (NYSEAMERICAN:OGEN) last posted its earnings results on Thursday, August 13th. The company reported ($0.57) earnings per share (EPS) for the quarter.

Institutional Trading of Oragenics

A number of hedge funds have recently modified their holdings of the company. DRW Securities LLC lifted its holdings in shares of Oragenics by 82.4% during the 4th quarter. DRW Securities LLC now owns 112,709 shares of the company’s stock worth $88,000 after acquiring an additional 50,900 shares during the period. Bank of America Corp DE raised its position in Oragenics by 7,374.0% in the second quarter. Bank of America Corp DE now owns 15,546 shares of the company’s stock worth $59,000 after purchasing an additional 15,338 shares in the last quarter. Finally, XTX Topco Ltd bought a new position in Oragenics during the fourth quarter worth about $26,000. Institutional investors own 18.71% of the company’s stock.

About Oragenics

Oragenics, Inc is a clinical-stage biotechnology company focused on the research and development of novel anti-infective therapeutics targeting oral and mucosal diseases. Headquartered in Tampa, Florida, the company leverages proprietary technologies to address unmet needs in dental and oral healthcare, with an emphasis on innovative treatments that can improve patient outcomes and reduce reliance on traditional antibiotics.

The company’s lead product candidate, Oraprev™, is being developed as a pre-procedural rinse designed to reduce oral microbial load prior to dental procedures.